Education
About Us
Working with TipRanks
Follow Us
Incyte (INCY)
:INCY
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$53.56 - $83.95
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.70M
Market Cap
$15.18B
Enterprise Value$11.16B
Total Cash (Recent Filing)$2.41B
Total Debt (Recent Filing)$43.12M
Price to Earnings (P/E)17.7
Beta0.51
Next Earnings
Nov 04, 2025EPS Estimate
1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding195,276,140
10 Day Avg. Volume2,033,412
30 Day Avg. Volume1,701,413
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.53
Enterprise Value/Gross Profit2.74
Enterprise Value/Ebitda27.42
Forecast
1Y Price Target
$82.83Price Target Upside6.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Financial PerformanceINCY reported strong results with beats for Jakafi, Opzelura, and Niktimvo leading to total revenues that were 6% above consensus.
Product LaunchThe early Niktimvo launch showed significant strength, leading to increased sales estimates for 2025 and 2030.
Bears Say
Pipeline DevelopmentPipeline delays, including the JAK2V617Fi data delay, give pause to the company's longer-term outlook.
Revenue ChallengesOpzelura revenue is challenged by lower tube usage, which could impact growth expectations.
Incyte News
INCY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $53.56 and its highest was $83.95 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is $15.18B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is Nov 04, 2025 which is in 88 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Jul 29, 2025. The company reported $1.572 earnings per share for the quarter, beating the consensus estimate of $1.401 by $0.171.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.58.
How many shares outstanding does Incyte have?
Incyte has 195,276,140 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of $1.572 in its last earnings report, beating expectations of $1.401. Following the earnings report the stock price went up 10.291%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in INCY
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$82.83 (6.57% Upside)
$82.83 (6.57% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 88.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.73%
12-Months-Change
Fundamentals
Return on Equity
24.30%
Trailing 12-Months
Asset Growth
24.87%
Trailing 12-Months
Company Description
Incyte
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Headquartered in Wilmington, Delaware, Incyte operates primarily in the healthcare sector, with a specific emphasis on oncology and inflammation. Its core products include Jakafi (ruxolitinib), which is approved for the treatment of myelofibrosis and polycythemia vera, and other pipeline products aimed at addressing unmet medical needs in cancer and inflammatory diseases.
INCY Company Deck
INCY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, with significant revenue growth across key products like Opzelura and Jakafi. The successful launch of Niktimvo and positive R&D progress, particularly in hematology-oncology, were notable. However, increased R&D expenses, delays in data release, and competitive pressures in solid tumor oncology present challenges. Overall, the sentiment is cautiously optimistic.View all INCY earnings summariesINCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$82.83
▲(6.57% Upside)
Technical Analysis
Ownership Overview
15.70% Insiders
22.90% Mutual Funds
0.60% Other Institutional Investors
34.48% Public Companies and
Individual Investors